<DOC>
	<DOCNO>NCT03080805</DOCNO>
	<brief_summary>Pyrotinib oral tyrosine kinase inhibitor target HER-1 HER-2 receptor . This study randomize , open-label , multi-center , active-controlled , parallel design study combination pyrotinib capecitabine versus Lapatinib plus capecitabine HER2+ MBC patient , prior receive taxane trastuzumab.Patients randomize 1:1 ratio one follow treatment arms.Arm A : pyrotinib ( 400 mg daily ) + capecitabine ( 1000 mg/m^2 twice daily ) , Arm B : Lapatinib ( 1250 mg daily ) + capecitabine ( 1000 mg/m^2 twice daily ) .Patients receive either arm therapy occurrence death , disease progression , unacceptable toxicity , withdrawalof consent .</brief_summary>
	<brief_title>Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine Patients With HER2+ Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>1 . Aged ≥18 ≤70 year . 2 . ECOG performance status 0 1 . 3 . Life expectancy 12 week . 4 . According RECIST 1.1 , least one measurable lesion exist 5 . Histologically cytologic confirm HER2 positive metastatic breast cancer . 6 . Prior treatment trastuzumab ( ≥2 cycle metastatic setting , ≥3 month adjuvant/neoadjuvant set ) Taxane ( ≥2 cycle set unendurable AE progression treatment ) . 7 . Previously reveived 1 2 chemotherapy regimen metastasis ; Adjuvant/neoadjuvant therapy consider firstline therapy case recurrence progression adjuvant/neoadjuvant therapy ; Recurrence progression neoadjuvant therapy completion surgey ; Recurrence progression within 6 month adjuvant therapy completion . 8 . Required laboratory value include follow parameter : ANC : ≥ 1.5 x 10^9/L ; Platelet count : ≥ 90 x 10^9/L ; Hemoglobin : ≥ 90 g/L ; Total bilirubin : ≤ 1.5 x upper limit normal ( ULN ) ; ALT AST : ≤ 2 x ULN ( patient liver metastasis : ≤5 x ULN ) ; BUN Creatinine : ≤ 1x ULN ; CCR≥50 mL/min ; LVEF : ≥ 50 % ; QTcF : &lt; 450 m ( male ) ， &lt; 470 ms（female） ; 9 . Signed informed consent . 1 . Received capecitabine metastatic setting ; Failure unendurable AE completion within 6 month capecitabine treatment prior randomization adjuvant/neoadjuvant setting ; 2 . Received HER2 target tyrosine kinase inhibitor ( include Lapatinib , Neratinib Pyrotinib ) ; 3 . Cumulated dosage Doxorubincin &gt; 400 mg/m^2 Epirubicin &gt; 800 mg/m^2 equal dosage anthracycline drug adjuvant/neoadjuvant/metastatic setting ) ; 4 . Received surgery，chemotherapy , radiotherapy target therapy within 28 day prior randomization . Received hormone therapy within 7 day prior randomization ; 5 . Participated clinical trial within 28 day prior randomization . 6 . Known dihydro pyrimidine dehydrogenase（DPD）defect ; 7 . CT MRI confiemed brain metastasis ; 8 . Bone skin lesion unique target lesion ; 9 . Second malignancy , except cure skin basal cell carcinoma carcinoma insitu uterine cervix , screen ; 10 . Factors influence usage oral administration ( e.g . unable swallow , chronic diarrhea intestinal obstruction , etc . ) ; 11 . Uncontrolled third space effusion ( pleural fluid ascites ) drainage clinical intervention ; 12 . Receiving antitumour therapy inform consent ; 13 . Unprogressed last antitumour therapy , accord RECIST1.1 ; 14 . History kind Heart disease , include 1 ) Angina pectoris ; ( 2 ) Arrhythmia require medication clinical significance ; ( 3 ) Myocardial infarction ; ( 4 ) Heart failure ; ( 5 ) Any heart disease judge researcher suitable participate study , etc ; 15 . History Immunodeficiency , acquire congenital immunodeficiency ( HIV positive ) , history organ transplantation ; 16 . History neurological psychiatric disorder , include epilepsy dementia ; 17 . Concomitant disease judge investigator may bring serious harm safety patient completion study ; 18 . All female patient breastfeed period childbearing period positive pregnancy test result refuse take reliable method birth control study ; 19 . Any situation judge investigator suitable participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>